Skip to content

Borderline of CME/D3 Dissection for Local Advanced Right-sided Colon Cancer

Borderline of CME/D3 Dissection for Local Advanced Right-sided Colon Cancer(BLARCC): a Prospective, Multicenter Randomized Control Clinical Trial

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06709144
Acronym
BLARCC
Enrollment
896
Registered
2024-11-29
Start date
2024-07-01
Completion date
2032-06-30
Last updated
2024-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colon Cancer

Keywords

right side colon cancer, complete mesentery resection

Brief summary

The study was conducted on patients with advanced right-sided colon cancer, and the clinical pathological and prognostic data of the patients were compared between the two groups of patients who were randomly divided into those undergoing SMV and SMA left resection, with the aim of resolving the controversy over the left resection boundary of CME/D3 lymph node dissection through this study, and to clarify whether SMA left resection is superior to SMV left resection.

Interventions

PROCEDURESMA lymph node dissection

The lymph node dissection boundary is on the left side of the superior mesenteric artery (SMA)

PROCEDURESMV lymph node dissection

The lymph node dissection boundary is on the left side of the superior mesenteric vein (SMV)

Sponsors

Jiangxi Provincial Cancer Hospital
CollaboratorOTHER
Jiangsu Cancer Institute & Hospital
CollaboratorOTHER
Liaoning Cancer Hospital & Institute
CollaboratorOTHER
The First Affiliated Hospital of Soochow University
CollaboratorOTHER
Shanxi Province Cancer Hospital
CollaboratorOTHER
The First Affiliated Hospital of Shanxi Medical University
CollaboratorOTHER
Shaoxing People's Hospital
CollaboratorOTHER
Shaoxing Second Hospital
CollaboratorOTHER
Ningbo No. 1 Hospital
CollaboratorOTHER
Ningbo No.2 Hospital
CollaboratorOTHER
Jinhua Central Hospital
CollaboratorOTHER
Affiliated Hospital of Jiaxing University
CollaboratorOTHER
The First People's Hospital of Huzhou
CollaboratorOTHER
The Central Hospital of Lishui City
CollaboratorOTHER
Lishui Country People's Hospital
CollaboratorOTHER
Zhejiang University
CollaboratorOTHER
Yuyao People's Hospital
CollaboratorOTHER
The Third Affiliated Hospital of Wenzhou Medical University
CollaboratorOTHER
First Affiliated Hospital of Wenzhou Medical University
CollaboratorOTHER
Cancer Hospital of Guangxi Medical University
CollaboratorOTHER
Ningbo Medical Center Lihuili Hospital
CollaboratorOTHER_GOV
Ruijin Hospital
CollaboratorOTHER
Second Affiliated Hospital of Wenzhou Medical University
CollaboratorOTHER
First Affiliated Hospital of Zhejiang University
CollaboratorOTHER
Second Affiliated Hospital, School of Medicine, Zhejiang University
CollaboratorOTHER
Shanghai Cancer Hospital, China
CollaboratorOTHER
The Affiliated Tumor Hospital of Harbin Medical University
CollaboratorUNKNOWN
Shanghai 10th People's Hospital
CollaboratorOTHER
The Second Affiliated Hospital of Harbin Medical University
CollaboratorOTHER
Xiangshan No.1 People' s Hospital
CollaboratorUNKNOWN
Zhejiang Province People's Hospital
CollaboratorUNKNOWN
Sir Run Run Shaw Hospital
CollaboratorOTHER
Sun Yat-sen University Cancer Hosptial
CollaboratorUNKNOWN
Haixing Ju, MD
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 78 Years
Healthy volunteers
No

Inclusion criteria

* right side colon cancer(The primary lesion is located in the ileocecal region, ascending colon, hepatic flexure of colon, or proximal transverse colon) * T3-4 and/or N1-2M0 * Colonoscopy and pathological biopsy confirmed colon adenocarcinoma

Exclusion criteria

* T1-2N0M0 * Cannot undergo curative resection * Simultaneous multiple primary colorectal cancer or other diseases requiring segmental resection * Distant metastasis * Tumor invades surrounding organs, requiring joint organ resection * Emergency surgery is required for complications such as intestinal obstruction, perforation, and bleeding * Patients who have received neoadjuvant therapy before surgery * Pregnant or lactating women * Patients who are not suitable or unable to tolerate surgery

Design outcomes

Primary

MeasureTime frameDescription
3 year DFS3 years3 year disease free survival

Secondary

MeasureTime frameDescription
5 year OS5 years5 year Overall survival

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026